Given the tumour-suppressive nature of Hippo signalling components and the oncogenic nature of its effector transcription co-regulators, YAP and TAZ, targeting this pathway is a compelling therapeutic strategy to subvert cancer initiation and progression [52,53]. The gene discussed is WWTR1; the disease is neoplasm.